EANS-News: Epigenomics Signs Distribution Deal with DPC for Epi proColon in Middle East

Third distribution agreement for Epi proColon completes the picture
for the Middle East

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

Subtitle: Third distribution agreement for Epi proColon completes the
picture for the Middle East

BERLIN and SEATTLE, November 5, 2010 (euro adhoc) - Epigenomics AG
(Frankfurt Prime Standard: ECX), the cancer diagnostics company,
today announced that the company has signed an exclusive distributor
agreement with DPC LEBANON for the commercialization of Epigenomics´
Epi proColon test in Lebanon, United Arab Emirates, Saudi Arabia,
Qatar, Kuwait, Syria, Jordan and Egypt.

Epi proColon is the world´s first CE-marked molecular diagnostic test
for the early detection of colorectal cancer in blood. The test uses
Epigenomics´ proprietary colorectal cancer biomarker Septin9 in blood
plasma. DPC expects to begin marketing the test in the next few
weeks.

Colorectal cancer is the third leading cause of cancer-related death
in the Western world and is also major threat to public health
throughout the Middle East. The disease is highly curable when
detected at an early still localized stage. Survival chances,
however, diminish once the tumor has spread to distant organs and the
disease has become obvious with patients showing symptoms.

"We are delighted to be commercializing Epi proColon in Lebanon and
throughout the Middle East," Leila Macaron, General Manager of DPC
commented. "Early detection of colorectal cancer is critical to the
effective treatment of this disease and we believe that this blood
test is a simple procedure that can be easily incorporated into
clinical regimes and screening programs."

"Signing this deal with DPC completes the picture for the Middle East
following our recent deals in Turkey and Israel," commented Geert
Nygaard, Chief Executive Officer of Epigenomics. "DPC will join
DATEKS and Pronto as important partners in our continuously growing
distributor network for our Epi proColon product"

Epi proColon is currently marketed by Epigenomics directly in
Germany, Austria and Switzerland. Outside this home market, it is
Epigenomics´ strategy to make the CE-marked test broadly available
through a mix of direct commercialization and a distributor network.

-Ends-

Contact Epigenomics AG

Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368
pr@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics´ tests on the market and in development for
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially
increasing the patient´s chances of survival.

For development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc.
for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products.

The company is headquartered in Berlin, Germany, and has a wholly
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more
information, please visit Epigenomics´ website at
www.epigenomics.com.

Notes for editors

Epi proColon

Epi proColon, developed by Epigenomics, is a CE-marked test kit for
the detection of methylated DNA of the Septin9 gene in blood plasma.
This Septin9 biomarker has been shown in numerous clinical studies to
be closely associated with the presence of colorectal cancer and may
aid in the detection of this common cancer. Septin9 is one of the
best and most systematically validated biomarkers for the early
detection of colorectal cancer today. In particular, the recent
PRESEPT Study was a successful prospective evaluation of Epi proColon
detection of methylated Septin9 in a cohort of about 8,000
individuals representative of a typical screening population.

Epigenomics´ legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the USA have not
been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade